Surgery drug aims to shield cancer Patients' mental health
NCT ID NCT06624878
Summary
This study tested whether giving a single low dose of the drug esketamine during surgery could help prevent depression afterwards in women with ovarian cancer. Researchers compared esketamine to a placebo (saltwater) in 568 patients to see if it reduced depressive symptoms, improved sleep, and aided recovery. The goal was to ease the mental and physical burden following major cancer surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang cancer hospital
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.